- Home
- WMS vs JAZZ Comparison
WMS vs JAZZ Comparison
Compare WMS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WMS
- JAZZ
- Stock Information
- Founded
- WMS 1966
- JAZZ 2003
- Country
- WMS United States
- JAZZ Ireland
- Employees
- WMS N/A
- JAZZ N/A
- Industry
- WMS Containers/Packaging
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- WMS Consumer Discretionary
- JAZZ Health Care
- Exchange
- WMS Nasdaq
- JAZZ Nasdaq
- Market Cap
- WMS 8.6B
- JAZZ 7.3B
- IPO Year
- WMS 2014
- JAZZ 2007
- Fundamental
- Price
- WMS $109.92
- JAZZ $108.07
- Analyst Decision
- WMS Strong Buy
- JAZZ Strong Buy
- Analyst Count
- WMS 8
- JAZZ 13
- Target Price
- WMS $139.88
- JAZZ $181.85
- AVG Volume (30 Days)
- WMS 818.0K
- JAZZ 1.3M
- Earning Date
- WMS 05-15-2025
- JAZZ 05-06-2025
- Dividend Yield
- WMS 0.65%
- JAZZ N/A
- EPS Growth
- WMS N/A
- JAZZ 49.21
- EPS
- WMS 5.76
- JAZZ 7.51
- Revenue
- WMS $2,904,245,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- WMS $6.81
- JAZZ $5.92
- Revenue Next Year
- WMS $6.03
- JAZZ $4.22
- P/E Ratio
- WMS $19.09
- JAZZ $14.39
- Revenue Growth
- WMS 1.04
- JAZZ 5.76
- 52 Week Low
- WMS $93.92
- JAZZ $95.49
- 52 Week High
- WMS $179.57
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- WMS 45.22
- JAZZ 47.97
- Support Level
- WMS $108.02
- JAZZ $106.69
- Resistance Level
- WMS $111.82
- JAZZ $110.48
- Average True Range (ATR)
- WMS 4.24
- JAZZ 3.56
- MACD
- WMS -1.20
- JAZZ 0.55
- Stochastic Oscillator
- WMS 25.13
- JAZZ 68.77
About WMS Advanced Drainage Systems Inc.
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe; Infiltrator; International and Allied Products and Other. It generates maximum revenue from the Pipe segment. The company serves Agriculture; Aviation and Military; Mining; Residential; Transportation; Healthcare and Education and others.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.